Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Antineoplastic Activity of Metformin
Why Add A GLP-1 Agonist To Existing Treatment for Type 2 Diabetes?
Metabolic Disorders During Pregnancy and the Risk of Childhood Obesity
Letter from the Editor
We have all read about the use of AI (artificial intelligence) by companies such as Google, Amazon and Facebook, to know what we want to order before we even look for it. You can see that when you place an order and they offer to have the product to you in only a few hours. There is also evidence that this AI actually programs our thinking for us.
This week Emma Kammerer, L|E|C|O|M Bradenton School of Pharmacy, PharmD Candidate, shows that this kind of programming can be passed on from one generation to the next based on metabolic conditions, and once started does not seem to go away.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: FDA Approves Expanded Indication for Toujeo
The FDA approved an expanded indication for long acting insulin glargine injection 300 U/mL(Toujeo) to improve glucose response in children aged 6 years and older with diabetes.
TOP STORIES — Diabetes News and Research
Conflicting findings on metformin’s possible relationship to cancer.
Adding Dulaglutide, Liraglutide or Semaglutide (GLP-1 agonists) to existing treatment for type 2 diabetes has major cardiovascular benefits. Exenatide* and Lixisenatide were neutral for providing cardiovascular benefits.
Early life programming may contribute to the development of obesity.
Did You Know: How Important Are Vitamin D and Omega-3 Fatty Acid Supplements in Kidney Function for Type 2 Diabetes Patients?
It has long been thought that Vitamin D and Omega-3 fatty acids are beneficial for patients with type 2 diabetes who have signs of microalbumin in the urine. Few interventions exist to prevent or delay chronic kidney disease (CKD) in patients with type 2 diabetes (T2DM). A randomized clinical trial with a 2 × 2 factorial design was conducted among 1312 adults with type 2 diabetes. In this study, de Boer et al. report the results of the VITAL-DKD (Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease) study. The primary aim of the study was to evaluate the efficacy of vitamin D 2000 IU daily and omega-3 fatty acids for the prevention and treatment of CKD in patients with T2DM. Although the main findings do not support the use of either supplement, there are caveats. First, few of the VITAL-DKD participants had overt markers of kidney disease (only 13% had estimated glomerular filtration rate <60 mL/min/1.73m2, and 9% had urine albumin-to-creatinine ratio ≥30 mg/g). Participants also had nearly normal mean 25-hydroxyvitamin D concentration, and only 16% had insufficient levels (<20 ng/dL). These participant characteristics are unfortunate, as the study showed a nonsignificant trend for the benefit of vitamin D supplementation in those with lower baseline 25-hydroxyvitamin D levels and markers of kidney disease in subgroup analyses. Among adults with type 2 diabetes, supplementation with vitamin D3 or omega-3 fatty acids, compared with placebo, resulted in no significant difference in change in eGFR at five years. From the results, it was concluded that the use of vitamin D or omega-3 fatty acid supplementation could not be recommended for the preservation of kidney function among adults with type 2 diabetes.
https://jamanetwork.com/journals/jama/article-abstract/2755300
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Nadeen Ayad, BCPS, PharmD Candidate, Skaggs School of Pharmacy, University of Colorado
Jordan Boyd, PharmD. Candidate Florida Agricultural & Mechanical University School of Pharmacy
Andrew Daoud, PharmD Candidate, Florida A&M University
Hira Gohar, Florida A&M University, College of Pharmacy, PharmD Candidate
Emma Kammerer, L|E|C|O|M Bradenton School of Pharmacy, PharmD Candidate
Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.